ART-030

ART-030 is a preclinical-stage base-editing therapeutic candidate developed by ART-mRNA (also known as ART BioScience) for the treatment of Duchenne Muscular Dystrophy (DMD). The program utilizes base-editing technology, a precise form of genome editing that enables single-nucleotide conversions without inducing double-strand DNA breaks. ART-030 is designed to target the *DMD* gene to correct mutations or restore the reading frame, thereby facilitating the production of functional dystrophin protein. As of 2024, the asset is in the early discovery and preclinical development phase, leveraging the sponsor's expertise in mRNA-delivered genetic medicines.